Paraneoplastic syndrome is a rare and poorly understood systemic manifestation of malignancy that can involve multiple organ systems. Detection of the underlying malignancy is key to treatment. Sara Sheikhbahaei and colleagues from the Johns Hopkins University School of Medicine in Baltimore, Maryland, performed a systematic review and meta-analysis using published studies assessing the potential utility of whole-body18F-fluorodeoyglucose (FDG) with positron emission tomography (PET) or hybrid PET/computed tomography (PET/CT). {read more here}